Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab

by Osumi H, Matsusaka S, Suenaga M, Shinozaki E, Mizunuma N
Published 2015-08-01

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients

by Sato Y, Matsusaka S, Suenaga M, Shinozaki E, Mizunuma N
Published 2015-11-01

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer

by Ohhara Y, Suenaga M, Matsusaka S, Shinozaki E, Mizunuma N, Yamaguchi T
Published 2015-03-01

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

by Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Yamaguchi T
Published 2015-06-01

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer

by Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T
Published 2015-03-01

Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab

by Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Ozaka M, Ogura M, Chin K, Yamaguchi T
Published 2015-01-01

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)

by Suenaga M, Fujimoto Y, Matsusaka S, Shinozaki E, Akiyoshi T, Nagayama S, Fukunaga Y, Oya M, Ueno M, Mizunuma N, Yamaguchi T
Published 2015-05-01

Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis

by Kawakami K, Nakamoto E, Yokokawa T, Sugita K, Mae Y, Hagino A, Suenaga M, Mizunuma N, Oniyama S, Machida Y, Yamaguchi T, Hama T
Published 2015-04-01